Inhibition of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder tumor in rats by alpha-difluoromethylornithine.
The therapeutic effects of alpha-difluoromethylornithine (DFMO) on rats with bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) were examined. Eight-week-old male Wistar rats were given 0.05% BBN in their drinking water for a period of 4 weeks. Therapy (0.1% DFMO in their drinking water) was started at week 4 and all rats were killed at week 60. DFMO was seen to significantly reduce the incidence, the mean number and the total size of tumors. No side-effects of DFMO were noted, except alopecia, which started at month 7 of the therapy.
D000818:Animals; D002085:Butylhydroxybutylnitrosamine; D000518:Eflornithine / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
D002085:Butylhydroxybutylnitrosamine; D000518:Eflornithine